Bivalirudin Patent Expiration
Bivalirudin is Used for preventing blood clots in patients undergoing percutaneous coronary intervention (PCI). It was first introduced by Sandoz Inc
Bivalirudin Patents
Given below is the list of patents protecting Bivalirudin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Angiomax Rtu | US11903993 | Ready-to-use bivalirudin compositions | May 20, 2039 | Maia Pharms Inc |
| Angiomax Rtu | US11918622 | Ready-to-use bivalirudin compositions | May 20, 2039 | Maia Pharms Inc |
| Angiomax Rtu | US11992514 | Ready-to-use bivalirudin compositions | May 20, 2039 | Maia Pharms Inc |
| Angiomax |
US7582727 (Pediatric) | Pharmaceutical formulations of bivalirudin and processes of making the same | Jan 27, 2029 | Sandoz |
| Angiomax |
US7598343 (Pediatric) | Pharmaceutical formulations of bivalirudin and processes of making the same | Jan 27, 2029 | Sandoz |
| Angiomax | US7582727 | Pharmaceutical formulations of bivalirudin and processes of making the same | Jul 27, 2028 | Sandoz |
| Angiomax | US7598343 | Pharmaceutical formulations of bivalirudin and processes of making the same | Jul 27, 2028 | Sandoz |
| Angiomax |
US5196404 (Pediatric) | Inhibitors of thrombin |
Jun 15, 2015
(Expired) | Sandoz |
| Angiomax | US5196404 | Inhibitors of thrombin |
Dec 15, 2014
(Expired) | Sandoz |
Bivalirudin's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List